XML 45 R30.htm IDEA: XBRL DOCUMENT
v3.20.2

Collaborative Research and Development Agreements (Details) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | ---
Nov. 30, 2014 USD ($) target | Mar. 31, 2014 USD ($) | Sep. 30, 2020 USD ($) | Mar. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Sep. 30, 2019 USD ($) | Jun. 30, 2019 USD ($) | Sep. 30, 2018 USD ($) | Dec. 31, 2017 USD ($) | Jun. 30, 2017 USD ($) | Dec. 31, 2016 USD ($) | Sep. 30, 2016 USD ($) | Jun. 30, 2016 USD ($) | Mar. 31, 2016 USD ($) | Dec. 31, 2015 USD ($) | Jun. 30, 2015 USD ($) | Sep. 30, 2020 USD ($) milestone | Sep. 30, 2019 USD ($) | Dec. 31, 2011 USD ($) | Jun. 30, 2014 target
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  | $ 0 |  |  | $ 0 |  |  |  |  |  |  |  |  |  |  | $ 15,000,000 | $ 5,000,000 |  |
TESARO | Collaborative Research And Development Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront license fee received | $ 2,000,000.0 | $ 17,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of outstanding research and development targets | target | 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3
Milestone payments, contingent upon preclinical and clinical trial events (up to) | $ 18,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent upon certain U.S. and European regulatory submissions and approvals (up to) | 90,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments, contingent upon achievement of specified levels of worldwide sales (up to) | $ 165,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Agreement term following first commercial sale or expiration of the last to expire patent (in years) | 12 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of milestones achieved during period | milestone |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |
Collaboration revenue |  |  | 0 |  |  | 0 |  |  |  |  |  |  |  |  |  |  | $ 15,000,000.0 | 5,000,000.0 |  |
TESARO | Initiated in vivo toxicology studies using good laboratory practices (GLPs) | Anti-PD-1 (GSK4057190A/Dostarlimab) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones achieved, amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000,000.0 |  |  |  |
TESARO | Initiated in vivo toxicology studies using good laboratory practices (GLPs) | Anti-TIM-3 (GSK4069889A/Cobolimab) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones achieved, amount |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000,000.0 |  |  |  |  |
TESARO | Initiated in vivo toxicology studies using good laboratory practices (GLPs) | Anti-LAG-3 (GSK40974386) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones achieved, amount |  |  |  |  |  |  |  |  |  |  |  | $ 1,000,000.0 |  |  |  |  |  |  |  |
TESARO | IND clearance from the FDA | Anti-PD-1 (GSK4057190A/Dostarlimab) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones achieved, amount |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,000,000.0 |  |  |  |  |  |
TESARO | IND clearance from the FDA | Anti-TIM-3 (GSK4069889A/Cobolimab) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones achieved, amount |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,000,000.0 |  |  |  |  |  |  |
TESARO | IND clearance from the FDA | Anti-LAG-3 (GSK40974386) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones achieved, amount |  |  |  |  |  |  |  |  |  | $ 4,000,000.0 |  |  |  |  |  |  |  |  |  |
TESARO | Phase 2 clinical trial initiation | Anti-PD-1 (GSK4057190A/Dostarlimab) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones achieved, amount |  |  |  |  |  |  |  |  |  | $ 3,000,000.0 |  |  |  |  |  |  |  |  |  |
TESARO | Phase 2 clinical trial initiation | Anti-TIM-3 (GSK4069889A/Cobolimab) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones achieved, amount |  |  |  |  |  |  |  |  | $ 3,000,000.0 |  |  |  |  |  |  |  |  |  |  |
TESARO | Phase 2 clinical trial initiation | Anti-LAG-3 (GSK40974386) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones achieved, amount |  |  |  |  | $ 3,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
TESARO | Phase 3 clinical trial initiation | Anti-PD-1 (GSK4057190A/Dostarlimab) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones achieved, amount |  |  |  |  |  |  |  | $ 5,000,000.0 |  |  |  |  |  |  |  |  | 15,000,000.0 |  |  |
TESARO | Phase 3 clinical trial initiation - second indication [Domain] | Anti-PD-1 (GSK4057190A/Dostarlimab) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones achieved, amount |  |  |  |  |  |  | $ 5,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
TESARO | Filing of the first NDA - first indication | Anti-PD-1 (GSK4057190A/Dostarlimab) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones achieved, amount |  |  |  | $ 10,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
TESARO | Filing of the first MAA - first indication | Anti-PD-1 (GSK4057190A/Dostarlimab) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestones achieved, amount |  |  |  | $ 5,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Celgene Corporation | Collaborative Research And Development Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront license fee received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 6,000,000.0 |
Collaboration revenue |  |  | $ 0 |  |  | $ 0 |  |  |  |  |  |  |  |  |  |  | $ 0 | $ 0 |  |
Maximum milestone payments per target |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 53,000,000.0 |
Celgene Corporation | Initiated in vivo toxicology studies using good laboratory practices (GLPs) | Anti-PD-1 (CC-90006) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Event |  |  |  |  |  |  |  |  |  |  |  |  | $ 500,000 |  |  |  |  |  |  |
Celgene Corporation | Phase 1 clinical trial initiation | Anti-PD-1 (CC-90006) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone Event |  |  |  |  |  |  |  |  |  |  | $ 1,000,000.0 |  |  |  |  |  |  |  |  |

X
- Definition Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent + References No definition available. + Details
Name: | anab_RevenueRecognitionMilestoneMethodAgreementTermFollowingFirstCommercialSaleOrExpirationOfTheLastToExpirePatent
Namespace Prefix: | anab_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales + References No definition available. + Details
Name: | anab_RevenueRecognitionMilestoneMethodContingentUponAchievementOfSpecifiedLevelsOfWorldwideSales
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals + References No definition available. + Details
Name: | anab_RevenueRecognitionMilestoneMethodContingentUponCertainUnitedStatesAndEuropeanRegulatorySubmissionsAndApprovals
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events + References No definition available. + Details
Name: | anab_RevenueRecognitionMilestoneMethodContingentUponPreclinicalAndClinicalTrialEvents
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone + References No definition available. + Details
Name: | anab_RevenueRecognitionMilestoneMethodMaximumRevenuePerMilestone
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount + References No definition available. + Details
Name: | anab_RevenueRecognitionMilestoneMethodMilestonesAchievedDuringThePeriodAmount
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period + References No definition available. + Details
Name: | anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod
Namespace Prefix: | anab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets + References No definition available. + Details
Name: | anab_RevenueRecognitionMilestoneMethodNumberOfOutstandingResearchAndDevelopmentTargets
Namespace Prefix: | anab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received + References No definition available. + Details
Name: | anab_RevenueRecognitionMultipledeliverableArrangementsUpfrontFeeReceived
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue Recognized, Milestone Method, Milestone Payment Earned + References No definition available. + Details
Name: | anab_RevenueRecognizedMilestoneMethodMilestonePaymentEarned
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=anab_TESAROInc.AndTESARODevelopmentInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_InVivoToxicologyStudiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=anab_AnaptysBiogeneratedAntiPD1AntagonistAntibodyTSR042Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiTIM3AntagonistAntibodyTSR022Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiLAG3AntagonistAntibodyTSR033Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_ClearanceOfInvestigationalNewDrugFromFDAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_Phase2ClinicalTrialInitiationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_Phase3ClinicalTrialInitiationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_Phase3clinicaltrialinitiationsecondindicationDomain
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_FilingofNDAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_FilingofMMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=anab_CelgeneCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiPD1AntagonistAntibodyCC90006Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_Phase1ClinicalTrialInitiationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |